Our findings reinforce the growing awareness of the beneficial role of adiponectin-AMPK-FOXO-signaling pathway in the pathogenesis of NAFLD/NASH24, 25, suggesting that its therapeutic targeting could be exploited as a management strategy. This evidence concerns the gene PRKAA1 and metabolic dysfunction-associated steatotic liver disease.